Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators

Seminars in Oncology

Volumn 37, Issue 1, 2010, Pages 39-46

  Bardia, Aditya ^a   Loprinzi, Charles ^b   Grothey, Axel ^b   Nelson, Garth ^b   Alberts, Steven ^b   Menon, Smitha ^b   Thome, Stephan ^c   Gill, Sharlene ^d   Sargent, Dan ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; COLON CANCER; COLON RESECTION; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; SEER PROGRAM;

EID: 76749168885     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2009.12.005     Document Type: Article

References (11)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M.J. CA Cancer statistics, 2008. Cancer J Clin. 58 (2008) 71-96
2. André T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. N Engl J Med. 350 (2004) 2343-2351
3. de Gramont A., Tournigand C., André T., Larsen A.K., and Louvet C. Adjuvant therapy for stage II and III colorectal cancer. Semin Oncol 34 Suppl 1 (2007) S37-S40
4. Figueredo A., Coombes M.E., and Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev. (2008) CD005390
5. Ravdin P.M., Siminoff L.A., Davis G.J., et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 19 (2001) 980-991
6. Loprinzi C.L., and Thome S.D. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol. 19 (2000) 972-979
7. Loprinzi C.L., and Ravdin P.M. Decision-making for patients with early breast cancer: individualized decisions for and by patients and their physicians. JNCCN 1 (2003) 189-196
8. Gill S., Loprinzi C.L., Sargent D.J., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much?. J Clin Oncol. 22 (2004) 1797-1806
9. Loprinzi C.L., Ravdin P.M., De Laurentiis M., and Novotny P. Do American oncologists know how to use prognostic variables for patients with newly diagnosed primary breast cancer?. J Clin Oncol. 12 (1994) 1422-1426
10. Feinstein A.R., Sosin D.M., and Wells C.K. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 312 (1985) 1604-1608
11. Olivotto I.A., Bajdik C.D., Ravdin P.M., et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol. 23 (2005) 2716-2725